PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 33289952-0 2021 Application of PBPK model for coproporphyrin I to evaluate the impact of SLCO1B1 genotype, ethnicity, and sex on its inter-individual variability. coproporphyrin I 30-46 solute carrier organic anion transporter family member 1B1 Homo sapiens 73-80 33650309-7 2021 A significant positive correlation was observed between hemoglobin level and plasma CP-I concentration in participants without OATP1B1*15 allele (n = 265; rs = 0.35, p < 0.0001) and with OATP1B1*15 allele (n = 126; rs = 0.27, p = 0.0022). coproporphyrin I 84-88 solute carrier organic anion transporter family member 1B1 Homo sapiens 187-194 33289952-8 2021 Lower magnitude of CPI-drug interaction was simulated in 521CC subjects, suggesting the risk of under-estimation of CPI-drug interaction without prior OATP1B1 genotyping. coproporphyrin I 19-22 solute carrier organic anion transporter family member 1B1 Homo sapiens 151-158 33048456-0 2021 Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study. coproporphyrin I 0-16 solute carrier organic anion transporter family member 1B1 Homo sapiens 58-65 33048456-8 2021 This suggests that CP-I is superior to CP-III as an endogenous biomarker for evaluation of OATP1B1 inhibition. coproporphyrin I 19-23 solute carrier organic anion transporter family member 1B1 Homo sapiens 91-98 32723847-7 2020 Consistent with this hypothesis, PROB inhibited OATP1B1- and OATP1B3-mediated transport of CPI in a concentration-dependent manner, with IC50 values of 167 and 76.0 microM, respectively, in transporter overexpressing cell assay. coproporphyrin I 91-94 solute carrier organic anion transporter family member 1B1 Homo sapiens 48-55 32961019-0 2021 Substantially Increased Plasma Coproporphyrin-I Concentrations Associated with OATP1B1*15 Allele in Japanese General Population. coproporphyrin I 31-47 solute carrier organic anion transporter family member 1B1 Homo sapiens 79-86 32961019-2 2021 A few small-scale studies suggested that plasma CP-I concentration is affected by OATP1B1 polymorphism, but detailed studies are lacking. coproporphyrin I 48-52 solute carrier organic anion transporter family member 1B1 Homo sapiens 82-89 32961019-5 2021 Post-hoc analysis revealed significant increases in plasma CP-I concentration in OATP1B1*1b/*15 (p = 0.036), *1a/*15 (p = 0.0005) and *15/*15 (p = 0.0003) groups compared to OATP1B1*1b/*1b group. coproporphyrin I 59-63 solute carrier organic anion transporter family member 1B1 Homo sapiens 81-88 32961019-5 2021 Post-hoc analysis revealed significant increases in plasma CP-I concentration in OATP1B1*1b/*15 (p = 0.036), *1a/*15 (p = 0.0005) and *15/*15 (p = 0.0003) groups compared to OATP1B1*1b/*1b group. coproporphyrin I 59-63 solute carrier organic anion transporter family member 1B1 Homo sapiens 174-181 32723847-7 2020 Consistent with this hypothesis, PROB inhibited OATP1B1- and OATP1B3-mediated transport of CPI in a concentration-dependent manner, with IC50 values of 167 and 76.0 microM, respectively, in transporter overexpressing cell assay. coproporphyrin I 91-94 solute carrier organic anion transporter family member 1B3 Homo sapiens 61-68 32482623-0 2020 Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for OATP Inhibition. coproporphyrin I 30-46 solute carrier organic anion transporter family member 1A2 Homo sapiens 164-168 32482623-9 2020 Taken together, these results suggest that hepatic OATP considerably affects the disposition of CPI in animal models, indicating CPI is a sensitive and selective endogenous biomarker of OATP inhibition. coproporphyrin I 96-99 solute carrier organic anion transporter family member 1A2 Homo sapiens 51-55 32482623-9 2020 Taken together, these results suggest that hepatic OATP considerably affects the disposition of CPI in animal models, indicating CPI is a sensitive and selective endogenous biomarker of OATP inhibition. coproporphyrin I 96-99 solute carrier organic anion transporter family member 1A2 Homo sapiens 186-190 32482623-9 2020 Taken together, these results suggest that hepatic OATP considerably affects the disposition of CPI in animal models, indicating CPI is a sensitive and selective endogenous biomarker of OATP inhibition. coproporphyrin I 129-132 solute carrier organic anion transporter family member 1A2 Homo sapiens 51-55 32482623-9 2020 Taken together, these results suggest that hepatic OATP considerably affects the disposition of CPI in animal models, indicating CPI is a sensitive and selective endogenous biomarker of OATP inhibition. coproporphyrin I 129-132 solute carrier organic anion transporter family member 1A2 Homo sapiens 186-190 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 222-238 solute carrier organic anion transporter family member 1B1 Homo sapiens 75-82 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 222-238 solute carrier organic anion transporter family member 1B3 Homo sapiens 84-91 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 222-238 solute carrier organic anion transporter family member 2B1 Homo sapiens 97-104 27317801-9 2016 Collectively, we conclude that CP-I and CP-III in plasma and urine can be appropriate endogenous biomarkers specifically and reliably reflecting OATP inhibition, and thus the measurement of these molecules can serve as a useful tool to assess OATP drug-drug interaction liabilities in early clinical studies. coproporphyrin I 31-35 solute carrier organic anion transporter family member 1A2 Homo sapiens 145-149 30175555-0 2018 PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3. coproporphyrin I 17-33 solute carrier organic anion transporter family member 1B1 Homo sapiens 115-122 30175555-0 2018 PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3. coproporphyrin I 17-33 solute carrier organic anion transporter family member 1B3 Homo sapiens 127-134 28325716-0 2017 Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay. coproporphyrin I 0-16 ATP binding cassette subfamily C member 2 Homo sapiens 72-77 28325716-0 2017 Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay. coproporphyrin I 0-16 ATP binding cassette subfamily C member 2 Homo sapiens 79-83 28325716-0 2017 Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay. coproporphyrin I 0-16 ATP binding cassette subfamily C member 2 Homo sapiens 112-116 28325716-6 2017 Here, we demonstrate for the first time that coproporphyrin-I (CP-I) is a MRP2 substrate in membrane vesicles. coproporphyrin I 45-61 ATP binding cassette subfamily C member 2 Homo sapiens 74-78 28325716-6 2017 Here, we demonstrate for the first time that coproporphyrin-I (CP-I) is a MRP2 substrate in membrane vesicles. coproporphyrin I 63-67 ATP binding cassette subfamily C member 2 Homo sapiens 74-78 28325716-8 2017 Of the 47 compounds tested, 30 compounds were inhibitors of human MRP2 and 8 compounds (17%) stimulated MRP2-mediated CP-I transport. coproporphyrin I 118-122 ATP binding cassette subfamily C member 2 Homo sapiens 104-108 28325716-10 2017 We concluded that CP-I could be an alternative in vitro probe substrate replacing E17betaG for appreciating MRP2 interactions while minimizing potential false-negative results for MRP2 inhibition due to stimulatory effects. coproporphyrin I 18-22 ATP binding cassette subfamily C member 2 Homo sapiens 108-112 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 222-238 solute carrier organic anion transporter family member 2B1 Homo sapiens 121-128 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 240-243 solute carrier organic anion transporter family member 1B1 Homo sapiens 75-82 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 240-243 solute carrier organic anion transporter family member 1B3 Homo sapiens 84-91 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 240-243 solute carrier organic anion transporter family member 2B1 Homo sapiens 97-104 31879282-1 2020 Organic anion transporting polypeptides (OATPs), expressed in human liver (OATP1B1, OATP1B3, and OATP2B1) and intestine (OATP2B1), govern the pharmacokinetics (PK) of drugs (e.g., statins) and endogenous substrates (e.g., coproporphyrin I [CPI]). coproporphyrin I 240-243 solute carrier organic anion transporter family member 2B1 Homo sapiens 121-128 31879282-7 2020 In fact, most statins and CPI have been shown to present variously as substrates of RIF-inducible proteins such as CYP3A4, Pgp, MRP2, and BCRP. coproporphyrin I 26-29 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 115-121 31879282-7 2020 In fact, most statins and CPI have been shown to present variously as substrates of RIF-inducible proteins such as CYP3A4, Pgp, MRP2, and BCRP. coproporphyrin I 26-29 ATP binding cassette subfamily B member 1 Homo sapiens 123-126 31879282-7 2020 In fact, most statins and CPI have been shown to present variously as substrates of RIF-inducible proteins such as CYP3A4, Pgp, MRP2, and BCRP. coproporphyrin I 26-29 ATP binding cassette subfamily C member 2 Homo sapiens 128-132 31879282-7 2020 In fact, most statins and CPI have been shown to present variously as substrates of RIF-inducible proteins such as CYP3A4, Pgp, MRP2, and BCRP. coproporphyrin I 26-29 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 138-142 30982223-7 2019 In addition, this study provides the first evidence that SLCO1B1 c.521T>C genotype is significantly associated with CP-I but not CP-III levels. coproporphyrin I 119-123 solute carrier organic anion transporter family member 1B1 Homo sapiens 57-64 30528195-5 2019 Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. coproporphyrin I 58-74 solute carrier organic anion transporter family member 1B1 Homo sapiens 100-107 30528195-6 2019 In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities. coproporphyrin I 97-113 solute carrier organic anion transporter family member 1B1 Homo sapiens 193-200 30096834-1 2018 Previously we reported that coproporphyrin-I (CP-I) is an optimal probe substrate for multidrug resistance-associated protein 2 (MRP2), and stimulation of MRP2-mediated transport is probe substrate-dependent. coproporphyrin I 28-44 ATP binding cassette subfamily C member 2 Rattus norvegicus 86-127 30096834-1 2018 Previously we reported that coproporphyrin-I (CP-I) is an optimal probe substrate for multidrug resistance-associated protein 2 (MRP2), and stimulation of MRP2-mediated transport is probe substrate-dependent. coproporphyrin I 28-44 ATP binding cassette subfamily C member 2 Rattus norvegicus 129-133 30096834-1 2018 Previously we reported that coproporphyrin-I (CP-I) is an optimal probe substrate for multidrug resistance-associated protein 2 (MRP2), and stimulation of MRP2-mediated transport is probe substrate-dependent. coproporphyrin I 28-44 ATP binding cassette subfamily C member 2 Rattus norvegicus 155-159 30096834-1 2018 Previously we reported that coproporphyrin-I (CP-I) is an optimal probe substrate for multidrug resistance-associated protein 2 (MRP2), and stimulation of MRP2-mediated transport is probe substrate-dependent. coproporphyrin I 46-50 ATP binding cassette subfamily C member 2 Rattus norvegicus 86-127 30096834-1 2018 Previously we reported that coproporphyrin-I (CP-I) is an optimal probe substrate for multidrug resistance-associated protein 2 (MRP2), and stimulation of MRP2-mediated transport is probe substrate-dependent. coproporphyrin I 46-50 ATP binding cassette subfamily C member 2 Rattus norvegicus 129-133 30096834-1 2018 Previously we reported that coproporphyrin-I (CP-I) is an optimal probe substrate for multidrug resistance-associated protein 2 (MRP2), and stimulation of MRP2-mediated transport is probe substrate-dependent. coproporphyrin I 46-50 ATP binding cassette subfamily C member 2 Rattus norvegicus 155-159 30096834-3 2018 Similar to human MRP2 transport, CP-I was transported by rat Mrp2 in a typical Michaelis-Menten kinetics with apparent Km and Vmax values of 15 +- 6 microM and 161 +- 20 pmol/min/mg protein, respectively. coproporphyrin I 33-37 ATP binding cassette subfamily C member 2 Homo sapiens 17-21 30096834-3 2018 Similar to human MRP2 transport, CP-I was transported by rat Mrp2 in a typical Michaelis-Menten kinetics with apparent Km and Vmax values of 15 +- 6 microM and 161 +- 20 pmol/min/mg protein, respectively. coproporphyrin I 33-37 ATP binding cassette subfamily C member 2 Rattus norvegicus 61-65 30096834-5 2018 These compounds stimulated Mrp2-mediated CP-I transport in vitro. coproporphyrin I 41-45 ATP binding cassette subfamily C member 2 Rattus norvegicus 27-31 30096834-8 2018 We concluded that the in vitro stimulation of CP-I transport mediated by Mrp2 is not translatable in vivo, and proposed that the presence of endogenous compounds such as bilirubin in the liver may contribute to the in vitro to in vivo disconnect. coproporphyrin I 46-50 ATP binding cassette subfamily C member 2 Rattus norvegicus 73-77 20472612-4 2011 Here, we examine the biochemical basis of the modulation of the TLR4 pathway by hemin (iron(III)-protoporphyrin IX) and its metabolic, oxidated derivative coprohemin (iron(III)-coproporphyrin I). coproporphyrin I 177-193 toll like receptor 4 Homo sapiens 64-68 20800521-1 2010 We present the first systematic molecular modeling study of the binding properties of murine (mHBP) and human (hHBP) p22HBP protein (heme-binding protein) with four tetrapyrrole ring systems belonging to the heme biosynthetic pathway: iron protoporphyrin IX (HEMIN), protoporphyrin IX (PPIX), coproporphyrin III (CPIII), coproporphyrin I (CPI). coproporphyrin I 293-309 heme binding protein 1 Homo sapiens 117-123 11504054-2 2001 Binding constants of human serum albumin (HSA) to four biological porphyrins (uroporphyrin I, heptacarboxylporphyrin, coproporphyrin I, protoporphyrin IX), which possess a wide range of hydrophobicity, were estimated by ACE. coproporphyrin I 118-134 albumin Homo sapiens 27-40 34580865-8 2021 In conclusion, these data indicate that plasma CPI outperforms CPIII in detecting altered OATP1B1 function, but GCDCA-3G is an even more sensitive OATP1B1 biomarker than CPI. coproporphyrin I 47-50 solute carrier organic anion transporter family member 1B1 Homo sapiens 90-97 34319605-6 2021 OATP1B1*15 carriers tended to have higher CP-I concentration compared to non-carriers. coproporphyrin I 42-46 solute carrier organic anion transporter family member 1B1 Homo sapiens 0-7 34319605-8 2021 Multiple logistic regression analysis by stepwise selection identified plasma CMPF concentration and OATP1B1*15 allele as significant factors independently affecting plasma CP-I concentration at baseline and at the next visit, respectively. coproporphyrin I 173-177 solute carrier organic anion transporter family member 1B1 Homo sapiens 101-108 34594217-5 2021 Compared to reference OATP2B1, the transport activities of the c.332G>A, c.601G>A and c.1457C>T variants were reduced among the substrates examined (estrone sulfate, DHEAS, CPI, CPIII and rosuvastatin), although there were substrate-dependent effects. coproporphyrin I 173-176 solute carrier organic anion transporter family member 2B1 Homo sapiens 22-29 34594217-8 2021 In the clinical cohort, the SLCO2B1 c.935G>A allele was associated with both higher plasma CPI (42%) and CPIII (31%) concentrations, while SLCO2B1 c.917G>A was linked to lower plasma CPIII by 28% after accounting for the effects of age, sex, and SLCO1B1 genotypes. coproporphyrin I 91-94 solute carrier organic anion transporter family member 2B1 Homo sapiens 28-35 35545255-8 2022 Based on the EC50 and Emax-values and the known circulating concentrations of 13cisRA and its metabolites after isotretinoin dosing, a 55% decrease in OATP1B1 activity was predicted in vivo In vivo DDI potential was evaluated clinically in subjects dosed with isotretinoin for up to 20 weeks using coproporphyrin-I (CP-I) as an OATP1B1 biomarker. coproporphyrin I 298-314 solute carrier organic anion transporter family member 1B1 Homo sapiens 151-158 35545255-8 2022 Based on the EC50 and Emax-values and the known circulating concentrations of 13cisRA and its metabolites after isotretinoin dosing, a 55% decrease in OATP1B1 activity was predicted in vivo In vivo DDI potential was evaluated clinically in subjects dosed with isotretinoin for up to 20 weeks using coproporphyrin-I (CP-I) as an OATP1B1 biomarker. coproporphyrin I 316-320 solute carrier organic anion transporter family member 1B1 Homo sapiens 151-158